Amlodipine, an L-type Ca2+ channel inhibitor, regulates release of extracellular vesicles from tumor cells
Carcinogenesis · 2025
DOI: 10.1093/carcin/bgaf016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2025. Verfasst von Sujan K Mondal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5117 Centre Ave, Suite 1.32, Pittsburgh, PA 15213, …. Hauptthemen laut MEDLINE: Amlodipine, Calcium Channel Blockers, Extracellular Vesicles, Neoplasms. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NIDCR NIH HHS.
Abstract (Originalsprache)
Tumor cells produce/release tumor-derived exosomes (TEX) which promote tumor growth, drive immune suppression, and interfere with immune therapies. Amlodipine, a calcium flux inhibitor, may block TEX release by tumor cells. Amlodipine’s potential as a drug blocking TEX release was evaluated. We measured tumor growth, TEX numbers, phenotype, and molecular content in murine SCCVII and human cancer cell lines. Cell lysates and TEX were tested for expression of autophagy-related proteins by western blots (WBs). Tumor growth in mice, histopathology, T-cell infiltrations, and TEX production by SCCVII treated with amlodipine were measured. Numbers and protein content of TEX eluted from tumor explants were studied by flow cytometry and WBs. Amlodipine used in vitro at 0.5–5 µM was nontoxic, did not impair tumor cell viability, reduced cell proliferation, and decreased TEX production. It reduced PD-L1 and Rab11 content of TEX, altered tumor cell size/shape, induced vesicle accumulations in the cytosol, and upregulated expression levels of autophagy-related proteins, ATG7, Beclin-1, and LC3. In vivo, daily treatment of established SCCVII with amlodipine (10 mg/kg) inhibited tumor growth (P < 0.001), increased CD8+ T-cell infiltration into tumor, decreased TEX production, and altered PD-L1, Rab11, and FasL content of TEX. Amlodipine delivered in vitro to tumor cells or in vivo to tumor-bearing mice interferes with tumor growth and TEX production, induces tumor autophagy, reduces circulating TEX numbers, and alters the TEX immunosuppressive signature. Amlodipine emerges as a potentially promising drug for removing immunosuppressive TEX in cancer subjects who are candidates for immune therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5117 Centre Ave, Suite 1.32, Pittsburgh, PA 15213, United States.
- Department of Human Genetics, School of Public Health, University of Pittsburgh, UPMC Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213, United States.
- Department of Medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213, United States.
- Departments of Immunology and Otolaryngology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5117 Centre Ave, Suite 1.32, Pittsburgh, PA 15213, United States.
ORCID-Profile: Theresa L Whiteside
Förderung
- NIH HHS
- NCI NIH HHS
- NIDCR NIH HHS
- National Institutes of Health
Zitieren
APA
Mondal, S. K., Hong, C. S., Han, J., Diergaarde, B., Zandberg, D. P., & Whiteside, T. L. (2025). Amlodipine, an L-type Ca2+ channel inhibitor, regulates release of extracellular vesicles from tumor cells. Carcinogenesis. https://doi.org/10.1093/carcin/bgaf016
Vancouver
Mondal SK, Hong CS, Han J, Diergaarde B, Zandberg DP, Whiteside TL. Amlodipine, an L-type Ca2+ channel inhibitor, regulates release of extracellular vesicles from tumor cells. Carcinogenesis. 2025. doi:10.1093/carcin/bgaf016
BibTeX
@article{Mondal2025,
author = {Mondal, Sujan K and Hong, Chang-Sook and Han, Jie and Diergaarde, Brenda and Zandberg, Dan P and Whiteside, Theresa L},
title = {Amlodipine, an L-type Ca2+ channel inhibitor, regulates release of extracellular vesicles from tumor cells},
journal = {Carcinogenesis},
year = {2025},
doi = {10.1093/carcin/bgaf016}
}
EUVIMED